Skip to content
Subscriber Only

Sanofi, Glaxo Covid Vaccine Works Well in Second-Chance Test

  • Vaccine generated antibody levels similar to natural infection
  • Drugmakers will assess lower dose as universal booster shot

Photographer: Eric Piermont/AFP/Getty Images

Updated on

Sanofi and GlaxoSmithKline Plc reported positive results from a redo of a mid-stage study for their Covid-19 vaccine, putting the delayed shot on track for possible clearance by the end of the year.

Volunteers showed a similar immune response to people who have recovered from the coronavirus, Sanofi said Monday. Those who’d already been infected had a higher response after just one injection, prompting the companies to decide to test a second formulation to bring to market as a booster.